The percentage on each card is AXGN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.
● The Motley FoolNov 16, 2026 · 17:00 ET
AxoGen: 3 Key Takeaways for Long-Term Investors
AxoGen raised full-year 2026 revenue guidance to at least $290 million. Commercial payer coverage for Avance reached 96% of covered U.S. lives.…
● GlobeNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, to…
GMED vs. AXGN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for those looking for under…
Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next decade. Q3 2026 saw 26% revenue growth, 45% adjusted EBITDA growth,…
AxoGen NASDAQ: AXGN reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets. The company also rai…
● Zacks Investment ResearchOct 28, 2026 · 09:36 ET
AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.…
● Zacks Investment ResearchOct 21, 2026 · 11:06 ET
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…
● Zacks Investment ResearchOct 16, 2026 · 12:40 ET
GMED or AXGN: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better bang for their buck rig…
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings es…
Axogen Inc (AXGN) Shares Fall 3.0% -- GF Value Says Still Overvalued
On September 22, 2026, Axogen Inc (AXGN) shares fell by 3.0%, closing at $44.54. The stock is currently trading within a 52-week range of $15.27 to $52.91.…
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.…
2 Medical-Device Stocks Lighting Up the Options Pits
Medical-device stocks Cooper Companies Inc (NASDAQ:COO) and Axogen Inc (NASDAQ:AXGN) are both sharply lower following separate company developments, and options traders are chiming in.…
● GlobeNewsWireSep 10, 2026 · 06:01 ETCOMPANY'S OWN WORDS
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of …
● GlobeNewsWireSep 10, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen's addressable market within its focus markets…
Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100
On August 26, 2026, Axogen Inc (AXGN) shares rose 3.3% to a current price of $51.58, continuing a strong upward trend. Over the past year, the stock has surged…
Article counts from the last market-wide feed page, across every symbol we track and not just AXGN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.